Vaccine maker announces new data on the effectiveness of its drug against coronavirus after the completion of the third phase of clinical trials
American biotech company Moderna has downgraded the effectiveness of its coronavirus vaccine in the third phase of trials.
DW reports about it with reference to the data of the company.
According to the latest clinical studies, the Moderna vaccine, created using mRNA technology, prevents infection in 90 percent of cases, and severe disease in 95 percent.
It is noted that more than 30 thousand volunteers took part in the third phase of clinical trials.
Note, in December 2020, Moderna estimated the effectiveness of its vaccine at 94.1 percent.
Recall, according to a study published in the American Journal of Obstetrics and Gynecology, coronavirus vaccines produced by Pfizer and Moderna are considered safe and effective for pregnant women.
In February, Moderna announced that it has developed an updated version of its COVID-19 vaccine that is effective against the South African variant of the coronavirus.